» Articles » PMID: 29351445

Impact of HIV Infection on α-antitrypsin in the Lung

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Emphysema is one of the most common lung diseases in HIV individuals. The pathogenesis of HIV-associated emphysema remains unclear; however, radiographic distribution and earlier age of presentation of emphysema in the lungs of HIV patients are similar to deficiency of α-antitrypsin (A1AT), a key elastase inhibitor in the lung. Reduced levels of circulating A1AT in HIV patients suggest a potential mechanism for emphysema development. In the present study we asked if A1AT levels and activity in the bronchoalveolar lavage fluid (BALF) differ in HIV and HIV patients with and without emphysema. A1AT levels were measured by ELISA in plasma and BALF from a cohort of 21 HIV and 29 HIV patients with or without emphysematous changes on chest CT scan. To analyze A1AT function, we measured elastase activity in the BALF and assessed oxidation and polymerization of A1AT by Western blotting. Total A1AT was increased in the BALF, but not in the plasma, of HIV compared with HIV patients, regardless of the presence or absence of emphysema. However, antielastase activity was decreased in BALF from HIV patients, suggesting impaired A1AT function. Higher levels of the oxidized form of A1AT were detected in BALF from HIV than HIV patients, which may account for the decreased antielastase activity. These findings suggest that, in the lungs of HIV patients, posttranslational modifications of A1AT produce a "functional deficiency" of this critical elastase inhibitor, which may contribute to emphysema development.

Citing Articles

Pulmonary function tests and their associated factors in people living with HIV at Jimma medical center; Ethiopia: a comparative cross-sectional study.

Teshome Azezew M, Gobena T, Mengstie M, Mulat E Front Reprod Health. 2023; 5:1178304.

PMID: 37901155 PMC: 10611469. DOI: 10.3389/frph.2023.1178304.


Pathogenesis and management of emphysema in people with HIV.

Kreniske J, Kaner R, Glesby M Expert Rev Respir Med. 2023; 17(10):873-887.

PMID: 37848398 PMC: 10872640. DOI: 10.1080/17476348.2023.2272702.


Severe COVID-19 Illness and α1-Antitrypsin Deficiency: COVID-AATD Study.

Rodriguez Hermosa J, Vargas Centanaro G, Estela Gonzalez Castro M, Miravitlles M, Lazaro-Asegurado L, Jimenez-Rodriguez B Biomedicines. 2023; 11(2).

PMID: 36831051 PMC: 9953718. DOI: 10.3390/biomedicines11020516.


World AIDS Day 2021: highlighting the pulmonary complications of HIV/AIDS.

Morty R, Morris A Am J Physiol Lung Cell Mol Physiol. 2021; 321(6):L1069-L1071.

PMID: 34816744 PMC: 8715024. DOI: 10.1152/ajplung.00471.2021.


Can Alpha-1 Antitrypsin Levels be Used to Predict the Prognosis of COVID-19 Therapy?.

Atik E, Ozdemir N, Demirkan K Turk J Pharm Sci. 2021; 17(6):576-577.

PMID: 33389945 PMC: 7786071. DOI: 10.4274/tjps.galenos.2020.20727.


References
1.
Justice A, Dombrowski E, Conigliaro J, Fultz S, Gibson D, Madenwald T . Veterans Aging Cohort Study (VACS): Overview and description. Med Care. 2006; 44(8 Suppl 2):S13-24. PMC: 3049942. DOI: 10.1097/01.mlr.0000223741.02074.66. View

2.
Tuder R, Yoshida T, Arap W, Pasqualini R, Petrache I . State of the art. Cellular and molecular mechanisms of alveolar destruction in emphysema: an evolutionary perspective. Proc Am Thorac Soc. 2006; 3(6):503-10. PMC: 2647641. DOI: 10.1513/pats.200603-054MS. View

3.
Kelly E, M Greene C, Carroll T, McElvaney N, ONeill S . Alpha-1 antitrypsin deficiency. Respir Med. 2010; 104(6):763-72. DOI: 10.1016/j.rmed.2010.01.016. View

4.
Hankinson J, Odencrantz J, Fedan K . Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999; 159(1):179-87. DOI: 10.1164/ajrccm.159.1.9712108. View

5.
Cichy J, Potempa J, Travis J . Biosynthesis of alpha1-proteinase inhibitor by human lung-derived epithelial cells. J Biol Chem. 1997; 272(13):8250-5. DOI: 10.1074/jbc.272.13.8250. View